Cancer treatments

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

Saturday, January 16, 2021 - 12:39am

ENHERTU is also approved in Japan for HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy based on the DESTINY-Gastric01 trial.

Key Points: 
  • ENHERTU is also approved in Japan for HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy based on the DESTINY-Gastric01 trial.
  • ENHERTU previously received Priority Review and Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of patients with previously treated HER2 positive metastatic gastric cancer, as well as Orphan Drug Designation (ODD) for patients with gastric cancer, including gastroesophageal junction cancer.
  • Two additional phase 2 trials, DESTINY-Gastric02 and DESTINY-Gastric03 , are underway, further evaluating the use of ENHERTU in patients with HER2 positive metastatic gastric cancer.
  • ENHERTU (6.4 mg/kg) is also approved in the U.S. and Japan for the treatment of previously treated patients with HER2 positive metastatic gastric cancer based on the DESTINY-Gastric01 trial.

Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

Friday, January 15, 2021 - 1:30pm

The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 17, 2021.

Key Points: 
  • The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 17, 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210115005163/en/
    Data presented today at ASCO GI continue to demonstrate the potential of zanidatamab in advanced HER2-expressing cancers with high unmet need.
  • The data being reported are from HER2-expressing GEA patients who received zanidatamab either as monotherapy (n=35) or in combination with chemotherapies (n=28).
  • The updated and new results are being presented today in a poster session at the ASCO Gastrointestinal Cancers Symposium.

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

Friday, January 15, 2021 - 1:03pm

The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).

Key Points: 
  • The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).
  • The initial response rate is promising, and thus far there has not been significant additive toxicity from AB680 to chemotherapy.
  • AB680 is currently in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer.
  • AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Thursday, January 14, 2021 - 9:30pm

The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Key Points: 
  • The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
  • FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer.
  • Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas.
  • Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer.

City of Hope Scientists Have Developed a Precision Medicine Tool That Predicts If Chemotherapy Will Produce Debilitating Side Effects in Older Adults

Thursday, January 14, 2021 - 9:00pm

(Photo credit: City of Hope)

Key Points: 
  • (Photo credit: City of Hope)
    This first-of-its-kind risk assessment tool called the Cancer and Aging Research Group-Breast Cancer (CARG-BC) Score helps oncologists make personalized treatment recommendations.
  • Oncologists can discuss the score and its significance with early-stage breast cancer patients age 65 or older.
  • Though chemotherapy is an effective way to treat early-stage breast cancer, it also carries a risk of side effects.
  • As a next step, the researchers will look to improve the chemotherapy toxicity risk assessment tool with more biological markers.

AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer

Wednesday, January 13, 2021 - 2:00pm

1 39 abstracts at WCLC 2020 will feature AstraZeneca medicines and pipeline molecules, of which 24 are company-sponsored or supported.

Key Points: 
  • 1 39 abstracts at WCLC 2020 will feature AstraZeneca medicines and pipeline molecules, of which 24 are company-sponsored or supported.
  • Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU.
  • In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients.
  • EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumor tissue and cytology samples.

Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors

Wednesday, January 13, 2021 - 1:00pm

Expansion cohorts in INNATE will address multiple different patient populations, including PD-(L)1 inhibitor nave patients with both PD-(L)1 inhibitor sensitive and resistant tumor types, and PD-(L)1 inhibitor experienced patients whose tumors were resistant to PD-(L)1 inhibitors.

Key Points: 
  • Expansion cohorts in INNATE will address multiple different patient populations, including PD-(L)1 inhibitor nave patients with both PD-(L)1 inhibitor sensitive and resistant tumor types, and PD-(L)1 inhibitor experienced patients whose tumors were resistant to PD-(L)1 inhibitors.
  • A Phase 1 clinical study named INNATE (NCT04669899), for JTX-8064 as a monotherapy and in combination with JTX-4014 or pembrolizumab, is currently enrolling patients with advanced solid tumors.
  • JTX-4014 is currently being assessed in the INNATE Phase 1 trial (NCT04669899) in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
  • A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounces internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors.

Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium

Monday, January 11, 2021 - 1:08pm

Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA treated patients.

Key Points: 
  • Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA treated patients.
  • Hepatotoxicity.Across clinical studies enrolling 1,327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients.
  • 2% of patients discontinued LENVIMA due to hepatic encephalopathy and 1% discontinued due to hepatic failure.
  • Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA.

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.

Monday, January 11, 2021 - 3:03am

The submission has been accepted by the Center of Drug Evaluation of the NMPA.

Key Points: 
  • The submission has been accepted by the Center of Drug Evaluation of the NMPA.
  • The population of SCLC patients account for about 15-20% of all lung cancer patients.
  • For the moment, the main clinical treatment methods of SCLC are radiotherapy and chemotherapy, which may only have short-term effect, and the disease is easy to relapse.
  • This also lays a good start for the further development of Chiauranib, which is the third original innovative drug discovered and developed by Chipscreen.

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

Monday, January 11, 2021 - 12:00pm

BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.

Key Points: 
  • BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021.
  • Initiation of two randomized Phase 2 studies for ALX 148 in combination with Keytruda in patients with HNSCC are planned in the first half of 2021.
  • ALX Oncology ended the third quarter of 2020 with approximately $259.5 million in cash, cash equivalents.
  • Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.